NCT06107829 - Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities | Biotech Hunter

Timeline

Start Date

January 31, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

February 28, 2027

Conditions

Tardive DyskinesiaIntellectual DisabilityDevelopmental Disabilities

Interventions

DRUG

Valbenazine Oral Capsule

Open-label twenty-four-week treatment with valbenazine oral capsules (up to 80 mg/day) to test the safety and effectiveness of this medication in ameliorating the signs of tardive dyskinesia in persons with intellectual disability.

Trial Locations (1)

44106

University Hospitals of Cleveland, Cleveland